Skip to content

A randomised clinical trial on heparin versus saline solution (NaCl 0,9%) in the maintenance of peripherical venous catheters - ND

A randomised clinical trial on heparin versus saline solution (NaCl 0,9%) in the maintenance of peripherical venous catheters - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-001347-21-IT
Enrollment
Unknown
Registered
2007-06-15
Start date
2007-03-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PVC flow maintenance MedDRA version: 6.1 Level: SOC Classification code 10047065

Interventions

Trade Name: EPSODILAVE Pharmaceutical Form: Solution for infusion INN or Proposed INN: Heparin Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 250-

Sponsors

OSPEDALE POLICLINICO S. MATTEO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: PVC hospitalized patients Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: patients with history of adverse events to heparin, with piastrinopenia or haemorragic diatesis that have been hospedalized for a period < 5 days

Design outcomes

Primary

MeasureTime frame
Main Objective: Verify if periodical washing with heparin solution 100 U.I./ml can reduce PVC occlusion and prevent complications of thrombophlebitis rispect to a control group using saline solution.;Secondary Objective: Verify any possible effects of reduction of PVC occlusion induced by heparin on hospitalization.;Primary end point(s): thrombophlebitis on site of catheter inserction; PVC occlusions

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026